GlobeNewswire

AND (Ticker: AND.AS) Launches new Health Alert Zones.

Share

Have your health exposure at your fingertips

Capelle aan den IJssel, the Netherlands, 1 October 2020- AND is proud to announce the launch of its new global Health Alert Zones API and website.

The AND team has joined forces with the GeoHealthApp team to develop a unique location-based Health Alert Zone risk evaluation. This API provides aggregated global information about COVID-19 pandemic statistics and health exposure evaluation, down to local level, across specific focus countries such as Germany ,  Switzerland, UK, USA, The Netherlands, Belgium, France and Italy.

The health exposure risk score is compiled using COVID-19 official statistics combined with expected exposure in up to 50 different types of locations (from shops, bars and restaurants, parks, beaches etc…) as well as the weather forecast and the day of the week. This results in a detailed risk assessment for areas as small as 100m2. Our algorithm estimates local behavior based on this local and dynamic data and then creates a health alert score for each region and area. This information can be either accessed via an API or displayed on a website using the AND MapTiler Technology.

With that information at their fingertips, people can make better informed decisions regarding their next destination and its associated health exposure. Businesses can also benefit from AND’s health alert zones by taking the appropriate safety measures when planning their logistics operations or deploying their services teams.

Key features of this API include

  • Up to date global COVID-19 (WHO) information, including historical data, in 200+ countries.
  • Health Exposure from country to street level in the focus countries.
  • Daily updates to global and local data.
  • Detailed local level information from official sources of the following focus countries: Germany, Switzerland, UK, USA, The Netherlands, Belgium, France and Italy, with more to be added soon.

Thierry Jaccoud, CEO at AND said: “The collaboration with the GeoHealthApp/ARIT-Services team has been beneficial on multiple levels. The GeoHealthApp/ARIT-Services team’s vision to reduce the spread of the virus by offering free information in an app works hand in hand with AND’s vision to improve safety and sustainability via tailor-made location-aware content. The latest app version includes GeoMap which offers both an overview of where app users are located and their status within the risk areas. Both mapping solutions are using AND’s MapTiler technology and the Health Alert Zones API. We now look forward to further enrich that API with users’ feedback.“

Dr. Med Maxim Gleser, Shareholder GeoHealthApp gGmbH said: “When we needed to complete our vision for a new app that not only included a COVID-19 tracker but also location-aware information through our in App GeoMap, we welcomed the idea to meet with the AND Team. AND immediately embraced and supported this new initiative. Unlike other COVID-19 apps, our app delivers a unique combination of COVID-19 tracker app and location-aware health information and works very well across borders and continents. The GeoHealthApp team in collaboration with the Health Tech Cluster in Switzerland wants to revolutionise how people use technology to reduce their health risk exposure and I think we are on the right track to achieve this.”

For more information about AND’s Health alert zones, visit www.health-alert-zones.com or www.and.com/health-alert-zones-demonstrator for further details about the GeoHealth app visit www.geohealthapp.de or their Facebook page

Ends 

About AND
AND is an innovative location-aware content and service provider. Our focus is to create and deliver market leading, relevant, innovative and tailored content which fosters a safer and more sustainable world. Using smart technology, we constantly enrich and update our global database and offer an end-to-end portfolio of location-aware products and services.

About GeoHealthApp GmBH
GeoHealth App is a Non-Profit Organization that aims to reduce the spread of COVID-19. Our goal is to customize COVID-19 protection measurements to maximise our users’ probability to stay healthy. At the same time our users should have the maximum amount of freedom. By utilizing Big Data and artificial intelligence we are at the forefront of creating the most advanced digital health tools against COVID-19.

Press Relations contact AND:
Caroline Bombart
Head of Marketing
Tel +31 (0)10 885 1200
Caroline.bombart@and.com

Press Relations contact GeoHealthApp:
Robert Sachartschenko
Managing Director & Co-Founder
Tel : +49 (0) 176 5785 4133
info@geohealthapp.de

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics receives FDA Fast Track designation for eprenetapopt in AML30.11.2020 16:31:31 CETPress release

STOCKHOLM, SWEDEN – November 30, 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for eprenetapopt in the treatment of patients with TP53 mutant acute myeloid leukemia (AML). The company previously received Breakthrough Therapy, Orphan Drug and Fast Track designations for eprenetapopt in the treatment of patients with TP53 mutant myelodysplastic syndromes (MDS). The FDA’s Fast Track designation is intended to facilitate the development and review of drug candidates that treat serious conditions and address an unmet medical need. A drug candidate that receives Fast Track designation may be eligible for more frequent interaction with the FDA to discuss the drug candidate’s development plan as well as eligibility for accelerated approval and priority review. Eprenetapopt (APR-246) is a small molecule that has demonstrated reactivation of mutant and inactivated p53 protein by restori

Karolinska Developments portföljbolag Aprea Therapeutics erhåller Fast Track designation från FDA för behandling med eprenetapopt vid AML30.11.2020 16:31:31 CETPressemelding

STOCKHOLM, SVERIGE 30 november 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att den amerikanska läkemedelsmyndigheten FDA har beviljat Fast Track designation för portföljbolaget Aprea Therapeutics läkemedelskandidat eprenetapopt vid behandling av TP53-mutant akut myeloisk leukemi (AML). Bolaget har tidigare erhållit Breakthrough-status, särläkemedelsstatus och Fast Track designation för eprenetapopt vid behandling av TP53-mutant myelodysplastiskt syndrom (MDS). FDA:s Fast Track designation är avsedd att underlätta utvecklingen och den regulatoriska granskningen av läkemedelskandidater som adresserar allvarliga sjukdomstillstånd och tillgodoser betydande medicinska behov. En läkemedelskandidat som erhåller Fast Track designation kan vara berättigad till frekventare interaktion med FDA för att diskutera den fortsatta utvecklingsplanen och ger dessutom möjlighet till påskyndad handläggning av en registreringsansökan. Eprenetapopt (APR-246) är en småmolekylär läke

CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER30.11.2020 16:20:00 CETPress release

Complete terms and conditions can be retrieved at http://www.riksbank.se https://www.riksbank.se/sv/penningpolitik/penningpolitiska-instrument/kop-av-foretagscertifikat/ Bid procedure, 2020-12-02CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date, i.e. with the latest maturity date as of 2021-06-02 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2020-11-23 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2020-12-02Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid vol

Olainfarm Group maintains its profit forecast, a short term decline in 9 month sales results30.11.2020 15:59:00 CETPress release

In 2020, the Olainfarm Group continued its ongoing activity in major sales markets. The highest sales in nine months in 2020 was in Latvia, reaching 28 738 thousand EUR, which is 232 thousand EUR or 1% higher than the same period year ago. Latvia sales represent 32% in Group revenues. Sales in Russia for the nine months period in 2020 amount to 20 590 thousand EUR which is a decrease from 2019 due to extra one-off shipment at the end of 2019 for consumption in the first quarter 2020 amounting to 6 million EUR. “Covid-19 pandemic and restrictions due to it have brought different challenges our way, but we understand how to tackle them, and are committed to reach our growth plans outlined in the company's 5-year strategy. As a long-term investment, we have established a subsidiary in Russia, which allows us to get insights from the medical community and market research so that our efforts are relevant and current to customer needs. I am happy to announce that the new business model in Ru

Kommuniké från extra bolagsstämma i Active Biotech samt justering av tidigare kommunicerad tidplan avseende nyemissionen30.11.2020 15:30:00 CETPressemelding

Extra bolagsstämma i Active Biotech AB (publ) hölls den 30 november 2020. Stämman beslutade, i enlighet med styrelsens förslag, om nyemission med företrädesrätt för aktieägarna. Genom nyemissionen ges högst 72 618 240 nya aktier ut. Två befintliga aktier berättigar till teckning av en ny aktie. Nyemissionen omfattas av vederlagsfria teckningsåtaganden och emissionsgarantier om cirka 40,0 miljoner kronor. Teckningskursen uppgår till 1,05 kronor per aktie. Avstämningsdag för rätt att delta i nyemissionen är den 4 januari 2021. Teckning av de nya aktierna ska ske under perioden 7 – 21 januari 2021. Ett prospekt avseende nyemissionen kommer att offentliggöras före teckningsperiodens början. Preliminär tidplan Sista dag för handel i Active Biotech-aktien inklusive rätt att delta i emissionen infaller den 29 december 2020, istället för den 30 december 2020 som tidigare har kommunicerats. 30 november 2020Extra bolagsstämma 29 december 2020Sista dag för handel i Active Biotech-aktien inklusive